This session is part of NAHEWD’s national webinar series Bridging HIV and SUD: Innovations in the Field. The series will highlight various innovative models and approaches to treating substance use disorder (SUD) in people at risk for and living with HIV. As clinical trials of psychedelic-assisted therapies progress, the potential of approved psilocybin and MDMA-assisted treatments for anxiety, mood, and substance use disorders (SUDs) looks increasingly promising. Clinicians interested in new mental healthcare treatment options for SUDs can learn about current treatment designs and published study outcomes to consider how psychedelic-assisted therapies might serve people at risk for and living with HIV.

Learning objectives:

• Identify hypothesized mechanisms of psychedelic-assisted interventions for substance use disorders.

• Critically examine key clinical components of psychedelic-assisted mental health treatments.

• Describe research to date on psychedelic-assisted psychotherapy for the treatment of mental health conditions.